Lung Cancer Clinical Trials Overview

SCCA Clinical Studies: Lung Cancer

Erlotinib + OSI-906 for NSCLC (UW10054)
A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Status Conditions Phase Study ID
Closed NSCLC Phase II UW10054

A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung carcinoma (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene who are Chemo naive.

Keith Eaton, MD
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Historically confirmed advanced NSCLC stages IIIB or IV;
  • Exon 19 deletion or exon 21 activating mutation in EGFR;
  • Formalin-fixed paraffin-embedded archival or fresh tissue sample representative of the tumor prior to randomization for EGFR mutation analysis to assess study eligibility must be provided unless EGFR mutation analysis is provided through a separate arrangement with OSI. Minimum tumor tissue requirement for patient eligibility is 66 microns in a form sufficient to generate five 10-micron thick tissue sections, and four 4-micron thick tissue sections with greater-than-or-equal-to 5 mm squared tumor area on each section;
  • Measurable disease according to RECIST (version 1.1);
  • ECOG performance status 0-1 (Appendix 13-2);
  • Must be able to take oral medication;
  • Fasting glucose <= 150 mg/dL (8.3 mmol/L). Concurrent use of non-insulinotropic anti hyperglycemic therapy is permitted if the dose has been stable for >= 4 weeks at the time of randomization;
  • Adequate hematopoietic, hepatic, and renal function as follows: Neutrophil count >= 1500/uL; Platelet count >= 100,000/uL; Serum creatinine <= 1.5 x ULN; Potassium, magnesium, and calcium within normal limits (supplementation is permitted); Total bilirubin <= 1.5 x ULN; and AST and ALT <= 2.5 x ULN, or <= 5 x ULN if patient has documented liver metastases;
  • Patients - both male and female - with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must agree to practice effective contraceptive measure throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to randomization. Men must agree not to donate sperm while on study drug and up to 90 days following the last dose of study drug;
  • Patients must provide written informed consent to participate in the study;
  • Patients may not have received chemotherapy for advanced NSCLC. Previous adjuvant and/or neo-adjuvant treatment for NSCLC is permitted;
  • Prior radiation therapy is permitted provided patients have recovered from the acute, toxic effects of radiotherapy prior to randomization. A minimum of 21 days must have elapsed between the end of radiotherapy and randomization; and
  • Prior surgery is permitted provided that the surgery was done >= 28 days prior to randomization and adequate wound healing has occurred prior to randomization.
Exclusions (conditions that would prevent participation in this study)
  • Prior exposure to agents directed at the HER axis (eg, erlotinib, gefitinib, and cetuximab); or
  • Prior IGF-1R inhibitor therapy; or
  • Malignancies other than NSCLC within the past 3 years (exceptions if curatively treated; basal or squamous cell carcinoma of skin; locally advanced prostate cancer; ductal carcinoma in situ of breast; in situ cervical carcinoma; and superficial bladder cancer);
  • Diabetes mellitus currently requiring insulinotropic or insulin therapy (Appendix 13-7);
  • Use of proton pump inhibitors such as omeprazole within 14 days prior to randomization (see Section H2-receptor antagonists such as ranitidine are not excluded (see Section;
  • Symptomatic brain metastases that are not stable, require steroids, or that have required radiation within 21 days prior to randomization;
  • Prior investigational agent within 21 days prior to randomization;
  • History of poorly controlled gastrointestinal disorders that could affect the absorption of study drug (eg, Crohn's disease or ulcerative colitis);
  • History (within last 6 months) of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac disease includes second/third degree heart block; clinically significant ischemic heart disease; superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but no ordinary physical activity results in fatigue, palpitation, or dyspnea);
  • History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (>= grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded;
  • Mean QTcF interval >= 450 msec at screening;
  • Use of drugs that have a known risk of causing Torsades de Pointes (TdP) ('Torsades List' on are prohibited within 14 days prior to randomization (see Appendix 13-3);
  • Use of strong/moderate CYP1A2 inhibitors such as ciprofloxacin and fluvoxamine. Other less potent CYP1A2 inhibitors/inducers are not excluded (see Appendix 13-5);
  • Use of strong/moderate CYP3A4 inhibitors and inducers (see Appendix 13-5);
  • History of cerebrovascular accident (CVA) within 6 months prior to randomization or that resulted in ongoing neurologic instability;
  • History of any psychiatric or neurologic condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent;
  • Pregnant or breast-feeding females;
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug; and/or
  • Active infection, serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization), symptomatic brain metastases, or serious chronic illness that would impair the ability of the patient to receive study drug.
Last Updated
December 21, 2012
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.